19 Oct 2015 07:00
Venn Life Sciences Holdings Plc
("Venn" or the "Company" or the "Group")
Appointment of Director
Venn Life Sciences (AIM: VENN), a growing Clinical Research Organisation providing clinical trial management and resourcing solutions to pharmaceutical, biotechnology and medical device clients, announces that following the completion of the acquisition of Kinesis Pharma B.V. ("Kinesis"), Mr Kees Groen, has been appointed as an Executive Director of Venn with immediate effect.
Mr Groen, aged 54, is a founder and managing director of Kinesis, and is a regulatory expert with significant experience in pharmaceutical research and development, both with regulatory authorities and in industry. He has been involved on a management and operational level in the fields of preclinical and clinical development, regulatory affairs and licensing for 25 years.
Tony Richardson, Chief Executive Officer of Venn said: "Keess' vast experience in all aspects of drug development will bring significant value to Venn Life Sciences. This appointment will add capability and capacity which will allow us to explore further acquisition opportunities. With this we can continue to build a successful and sustainable business for shareholders."
Information pursuant to Schedule Two, paragraph (g) of the AIM Rules is set out below:-
Mr Groen is beneficially interested in 4,780,320 ordinary shares in the Company, amounting to 8.03% of the issued share capital of the Company as part consideration for the purchase of Kinesis and are subject to a lock up period of 12 months from 16 October 2015.
Current directorships or partnerships | Directorships or partnerships in the last five years |
Oriental Flavour Investments BV | InPEC BV |
G&G Life Sciences BV |
|
Brant Life Sciences BV |
|
Cinmar Pharma BV |
|
Dieze Delta BV |
|
Orca therapeutics BV |
|
Mr Groen was a member of the Advisory Board of InPEC B.V a Phase 1 CRO, a company invested in by Kinesis Holding. InPEC was liquidated on 20 April 2010.
Save as disclosed above, there are no further disclosures required to be made in respect of the appointment under Schedule 2(g) of the AIM Rules for Companies.
Enquiries:
Venn Life Sciences Holdings Plc |
| |
David Evans, Non-Executive Chairman | Tel: +44(0) 7980 541 893 | |
Tony Richardson, Chief Executive Officer | Tel: +353 154 99 341 | |
|
| |
Zeus Capital (Nominated Adviser and Co-Broker) |
| |
Andrew Jones/Phil Walker | Tel: +44(0) 161 831 1512 | |
Dominic Wilson/Alex Davies | Tel: +44(0) 20 3829 5000 | |
Hybridan LLP (Co-Broker) Claire Louise Noyce |
Tel: +44(0) 20 3764 2341 | |
|
| |
Walbrook PR Ltd | Tel: +44(0)20 7933 8787 or venn@walbrookpr.com | |
Paul McManus | Mob: +44(0) 7980 541 893 | |
Lianne Cawthorne | Mob: +44(0) 7584 391 303 | |
About Venn Life Sciences:
Venn Life Sciences is a Clinical Research Organisation providing clinical trial management and resourcing solutions to pharmaceutical, biotechnology and medical device organisations. With dedicated operations in France, Germany, the Netherlands, the UK, Ireland and Europe wide representation - Venn specialises in rapid deployment and management of multisite projects. Venn also has an innovation division - Innovenn - focused primarily on breakthrough development opportunities in Skin Science.